Posted by Michael Wonder on 14 Apr 2021
Petition filed for better access to haemophilia A drug
14 April 2021 - Parents of paediatric patients with haemophilia A are demanding the regulator to change the criteria for reimbursement for JW Pharmaceutical’s Hemlibra subcutaneous injection (emicizumab).
In January, the government expanded the reimbursement scope but added failure of immune tolerance induction treatment as the criteria for reimbursement, which made it more difficult for paediatric patients to receive Hemlibra injection, parents said.
